Agios Pharmaceuticals, Inc.

Celgene Corporation

Merrimack Pharmaceuticals, Inc.

Servier Pharmaceuticals LLC

Les Laboratoires Servier

Samuel V Agresta

Hua Yang

Yanfeng Zhang

Chong-Hui Gu

David Schenkein

Liting Guo

Jianming Wang

Yan Zhou

Zhen Tang

Dmitri B Kirpotin

Daryl C Drummond

Thomas Joseph Wickham

Kyle MacBeth

Bart S Hendriks

Jorge DiMartino

Helen Lee

Daniel F Gaddy

Vivek Saroj Kumar Chopra

Laurie A Kenvin

Robert Douglas Knight

Krishnan Viswanadhan

Qiang Xu

Lenny Dang

Bruce A Silver

Charles Kung

Marvin Barry Cohen

Marvin B Cohen

Elizabeth A Merica

Yue Chen

Bruce Alan Silver

Leonard Luan Dang

Kyle J Macbeth

Laurie Kenvin

Provided are methods and compositions for treating acute myelogenous leukemia (AML) in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme, (S)&#x2014;N&#x2014;((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide in combination with cytarabine and doxorubicin or idarubicin as an induction therapy and either cytarabine or a combination of combination of mitoxantrone and etoposide as consolidation therapy.

Combination therapy for treating malignancies

Described herein are methods for using compounds that activate pyruvate kinase.

Methods of using pyruvate kinase activators

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme.

Therapy for treating malignancies

Provided are methods and compositions for treating AML in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and an AML induction and consolidation therapy.

Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.

Therapeutically active compounds and their methods of use

Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.

Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.

Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).

Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.

Compositions and methods for non-invasive imaging

Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.

Growing community of inventors

Lexington, MA, United States of America

Samuel V Agresta